Publications in collaboration with researchers from Heidelberg University (18)

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2018

  1. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv52-iv61

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2014

  1. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death

    Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180

  2. European perspective on multiple myeloma treatment strategies in 2014

    Oncologist, Vol. 19, Núm. 8, pp. 829-844

2012

  1. European perspective on multiple myeloma treatment strategies: Update following recent congresses

    Oncologist, Vol. 17, Núm. 5, pp. 592-606

2011

  1. Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3

    Blood

  2. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384

  3. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

    Oncologist, Vol. 16, Núm. 4, pp. 388-403

  4. Treatment of relapsed and refractory multiple myeloma in the era of novel agents

    Cancer Treatment Reviews, Vol. 37, Núm. 4, pp. 266-283

2010

  1. Current multiple myeloma treatment strategies with novel agents: A European perspective

    Oncologist, Vol. 15, Núm. 1, pp. 6-25

2009

  1. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2008

  1. Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study

    Leukemia, Vol. 22, Núm. 4, pp. 842-849

2007

  1. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

    Blood, Vol. 110, Núm. 10, pp. 3557-3560

2006

  1. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

    Bone Marrow Transplantation, Vol. 37, Núm. 12, pp. 1135-1141

2001

  1. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European group for blood and marrow transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 27, Núm. 5, pp. 511-515

1999

  1. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia

    Leukemia, Vol. 13, Núm. 1, pp. 110-118